Clinical Trial Update: Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure [Phase 3]

View source ↗

Summary

Phase 3 open-label extension studying TD-9855 for symptomatic neurogenic orthostatic hypotension due to primary autonomic failure was terminated; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomic Failure
• Symptomatic Neurogenic Orthostatic Hypotension

Drugs mentioned

• TD-9855

Snippet

Sponsor: Theravance Biopharma | Conditions: Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Status: TERMINATED | Results posted: 2022-11-30